A phase I/II multicenter, first-in-human study of DB-1311/ BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors

被引：3

作者：

Cheng, Y. ^{[1
]}

Wu, L. ^{[2
]}

Parsonson, A. ^{[3
]}

Amin, H. ^{[4
]}

Shi, J. ^{[5
]}

Lemech, C. ^{[6
]}

Sun, Y. ^{[7
]}

Schmidt, A. ^{[8
]}

Lv, D. ^{[9
]}

Li, M. ^{[10
]}

Zheng, T. ^{[11
]}

Chaudhry, A. ^{[12
]}

Gandhi, C. ^{[4
]}

Wang, Q. ^{[13
]}

Motino, D. A. Montoya ^{[14
]}

Abed, A. ^{[15
]}

Tibes, R. ^{[16
]}

Lu, X. ^{[17
]}

Gu, V. ^{[17
]}

Lisberg, A. E. ^{[18
]}

机构：

[1] Jilin Canc Hosp, Med Oncol, Changchun, Peoples R China

[2] Hunan Canc Hosp, Thorac Med Oncol Dept, Changsha, Peoples R China

[3] Nepean Canc Care Ctr, Dept Med Oncol, Kingswood, NSW, Australia

[4] BRCR Global, Med Oncol, Plantation, FL USA

[5] Linyi Canc Hosp, Med Oncol, Linyi, Shandong, Peoples R China

[6] Scientia Clin Res, Med Oncol, Randwick, NSW, Australia

[7] Shandong Canc Hosp & Inst, Dept Clin Res, Jinan, Peoples R China

[8] Univ Sunshine Coast, Dept Clin Res, Private Hosp, Birtinya, Qld, Australia

[9] Wenzhou Med Univ, Enze Hosp, Taizhou Hosp Zhejiang Prov, Dept Resp Med,Taizhou Enze Med Ctr, Taizhou, Peoples R China

[10] Zhengzhou Univ, Affiliated Hosp 1, Med Oncol Dept, Zhengzhou, Peoples R China

[11] Harbin Med Univ, Canc Hosp, Oncol Phase 1 Ward, Harbin, Peoples R China

[12] Summit Canc Ctr, Med Oncol, Spokane Valley, WA USA

[13] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Internal Med, Zhengzhou, Peoples R China

[14] Arizona Oncol, Med Oncol, Tucson, AZ USA

[15] Peel Hlth Campus, Oncol Dept, Mandurah, WA, Australia

[16] BioNTech SE, Clin Dev, Mainz, Germany

[17] Dual Biol, Clin Dev Dept, Shanghai, Peoples R China

[18] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Med, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.078

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

57O

引用

页码：S1426 / S1426

页数：1